Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta

NCT03852433 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03852433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03852433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2019
Completion date
September 28, 2022
Enrollment
175 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis delta